stockrow
Friday 6 November 2026
Export NMTC’s income statement to Excel — free account
NeuroOne Medical Technologies Corporation
NMTC Healthcare Medical Devices
NeuroOne Medical Technologies Corporation’s revenue for fiscal 2025 (year ended September 2025) was $9.1 million, up 163.5% from fiscal 2024.
- Revenue
- +16.3%
- EPS
- −27.8%
- Free cash flow
- +26.9%
Quarter to June 2026, against a year earlier
0.85
0.01
−1.16%
Follow NMTC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to September
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 2 | 0 | 2 | 2 | 3 | 9 | 9 | +36.4% | 11 | 13 | 21 | +32.1% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | (13.54) | 88.59 | 97.91 | 31.27 | 89.49 | 55.65 | +89.5 pt | ||||||
| EBT | 0 | (5) | (7) | (7) | (14) | (10) | (10) | (12) | (12) | (4) | (7) | +32.6% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (707.99) | (4,093.91) | (471.68) | (607.42) | (356.74) | (39.63) | (78.63) | (39.6) pt | ||||||
| Net income | 0 | 0 | (7) | (7) | (14) | (10) | (10) | (12) | (12) | (4) | (7) | +32.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 2.13 | 0.14 | 0.79 | 0.65 | 0.77 | 1.36 | 1.09 | n/m | |||||
| Earnings | (0.16) | (2.31) | (2.43) | (1.72) | (15.11) | (5.58) | (3.78) | (3.90) | (2.76) | (0.54) | (0.93) | +14.5% | ||||||
| Cash flow | (0.07) | (0.96) | 0.00 | (1.37) | (3.79) | (4.82) | (2.82) | (4.27) | (2.47) | (0.42) | (0.81) | +21.3% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | (0.14) | (0.04) | (0.10) | (0.12) | (0.03) | (0.01) | (0.01) | n/m | ||||||
| Free cash flow | (0.07) | (0.96) | 0.00 | (1.37) | (3.93) | (4.86) | (2.92) | (4.39) | (2.50) | (0.44) | (0.83) | +21.7% | ||||||
| Book value | (0.11) | (2.29) | (1.57) | (0.31) | 2.29 | 3.68 | 3.60 | 2.07 | 0.18 | 1.06 | 0.43 | n/m | ||||||
| Shares, m | 2 | 2 | 3 | 4 | 1 | 2 | 3 | 3 | 4 | 7 | 8 | +12.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 173.99 | 12.76 | 6.08 | 7.67 | 3.92 | 0.78 | 34.1 | ||||||
| P/B | — | — | — | — | 82.77 | 6.45 | 2.82 | 3.31 | 32.24 | 5.04 | 1.95 | 22.1 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 145.58 | 7.50 | 4.51 | 7.25 | 3.20 | 0.56 | 28.0 | ||||||
| EV/FCF | — | — | — | — | 0.00 | (4.11) | (2.04) | (1.16) | (2.25) | (9.97) | (0.74) | (3.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | (2) | — | (5) | (3) | (9) | (8) | (13) | (11) | (3) | (7) | +36.2% | |||||
| Capex | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1.4%) | ||||||
| Free cash flow | 0 | (2) | — | (5) | (4) | (9) | (8) | (13) | (11) | (3) | (7) | +36.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | (4) | (4) | (1) | 2 | 6 | 9 | 6 | 2 | 8 | 4 | n/m | |||||
| Net debt | 0 | 2 | 2 | 0 | (4) | (7) | (11) | (5) | (1) | (7) | (2) | +44.0% | ||||||
| Shareholders’ equity | 0 | (5) | (4) | (1) | 2 | 7 | 10 | 6 | 1 | 7 | 4 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (56.61) | (1,336.61) | (1,399.51) | (1,805.19) | (515.46) | (156.69) | (96.33) | (113.38) | (182.93) | (44.63) | (87.56) | +12.0 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (806.13) | 0.00 | (526.10) | (287.08) | (526.1) pt | ||||||
| ROE | 10.75 | 190.78 | 144.75 | 240.75 | (3,292.35) | (230.81) | (123.77) | (149.61) | (348.39) | (91.34) | (124.66) | (102.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 11 | 15 | 16 | 17 | 18 | — | +13.1% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.02 | 0.14 | 0.12 | 0.20 | 0.51 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Sep 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
NeuroOne Medical Technologies Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IRIX IRIDEX Corporation | $11.9M | — (loss-making) | — (loss-making) | −7.41% (below 0%: shrinking) | n/m | +130.24% (above 0%: growing) | 34.19% | (8.19%) | Compare |
| SINT SINTX TECHNOLOGIES, INC. | $11.5M | — (loss-making) | — (loss-making) | +952.88% (above 0%: growing) | n/m | +47.37% (above 0%: growing) | 62.19% | (74.66%) | Compare |
| BTCY Biotricity Inc. | $10.9M | — (loss-making) | — (loss-making) | +10.40% (above 0%: growing) | n/m | +235.83% (above 0%: growing) | 82.55% | 3.70% | Compare |
| AEMD Aethlon Medical, Inc. | $8.5M | — (loss-making) | — (loss-making) | +335.00% (above 0%: growing) | n/m | −11.13% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NMTC NeuroOne Medical Technologies Corporation | $7.8M | — (loss-making) | — (loss-making) | +16.33% (above 0%: growing) | n/m | +26.91% (above 0%: growing) | 59.94% | (122.87%) | |
| BMRA Biomerica, Inc. | $7.4M | — (loss-making) | 11.4× | −8.33% (below 0%: shrinking) | n/m | −199.25% (below 0%: shrinking) | 8.14% | (97.00%) | Compare |
| INBS Intelligent Bio Solutions Inc. | $5.8M | — (loss-making) | — (loss-making) | +51.10% (above 0%: growing) | n/m | −31.59% (below 0%: shrinking) | 43.23% | (360.19%) | Compare |
| TBIO Telesis Bio Inc. | $5.3M | — (loss-making) | — (loss-making) | −71.85% (below 0%: shrinking) | n/m | −17.96% (below 0%: shrinking) | 64.43% | (349.74%) | Compare |
| VNRX VolitionRX Limited | $5.3M | — (loss-making) | — (loss-making) | −1.97% (below 0%: shrinking) | n/m | +18.58% (above 0%: growing) | 100.00% | (1,042.39%) | Compare |
| Median of peers | $8.0M | — | — | +4.22% | — | +3.73% | 52.71% | (85.83%) |
Pay and ownership Proxy statement filed 9 March 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.15m | 1.25m | 52.60 |
| 2024 | 2.00m | 1.92m | 58.58 |
| 2023 | 989.56k | 716.28k | 52.66 |
Ownership
Directors and executive officers, together
11.80%
Merchant Adventure Fund, L.P.
8.30%
David Rosa
5.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement